Dr. Jonathan G. Stine, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 195
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
PA license MD461663 · VA license 0101247916
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 195
- Services billed
- 250
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Measurement of liver stiffness | 62 | 61 |
| Established patient office or other outpatient visit, 40-54 minutes | 61 | 57 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 21 | 14 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tacrolimus Other prescribers in Hershey, PA | 89 |
| Mycophenolic Acid (mycophenolate sodium) | 68 |
| Carvedilol Other prescribers in Hershey, PA | 64 |
| Xifaxan (rifaximin) Other prescribers in Hershey, PA | 53 |
| Omeprazole Other prescribers in Hershey, PA | 38 |
| Mycophenolate Mofetil Other prescribers in Hershey, PA | 32 |
| Ursodiol Other prescribers in Hershey, PA | 31 |
| Lactulose Other prescribers in Hershey, PA | 21 |
| Hydrocortisone Other prescribers in Hershey, PA | 21 |
| Rezdiffra (resmetirom) | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 10 payments worth $8,139 in total to this clinician.
| Madrigal Pharmaceuticals | $8,139 |
|---|
| Consulting Fee | $7,050 |
|---|---|
| Food and Beverage | $573 |
| Travel and Lodging | $516 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Madrigal Pharmaceuticals Apr 11, 2025 | Consulting Fee REZDIFFRA · LIVER DISEASE | $5,640 |
| Madrigal Pharmaceuticals Mar 10, 2025 | Consulting Fee REZDIFFRA · LIVER DISEASE | $1,410 |
| Madrigal Pharmaceuticals Apr 11, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to PHILADELPHIA, PA · in-kind | $303 |
| Madrigal Pharmaceuticals Apr 11, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to PHILADELPHIA, PA | $148 |
| Madrigal Pharmaceuticals Apr 12, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to PHILADELPHIA, PA · in-kind | $65.30 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $50,449 in research payments for these studies, mostly to the institutions running them.
- A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05519475 - A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fib…
AstraZeneca Pharmaceuticals LP - AZD2693, Cardiovascular, Renal and Metabolism
AstraZeneca UK Limited - A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.